Rigel Pharmaceuticals

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Rigel Pharmaceuticals excels in sales, faces awareness challenges ahead

Rigel Pharmaceuticals demonstrated strong sales performance and efficient cost management in Q4 2022.
The company faces challenges in raising awareness, maintaining persistency, and reaching profitability.
Exploring market opportunities, partnerships, and collaborations position Rigel for future growth.
Competitive trial results and a focus on persistency drive Rigel's competitive edge in the market.

Rigel Pharmaceuticals excels in Q1 with REZLIDHIA and TAVALISSE, faces prescribing behavior challenges

Rigel Pharmaceuticals showcased strong Q1 performance, particularly with REZLIDHIA and TAVALISSE, while facing challenges in understanding prescribing behavior.
The company's focus on differentiated positioning, academic-community growth, and strategic partnerships presents promising opportunities for future expansion.
Financial stability, positive clinician feedback, and ongoing pipeline advancements position Rigel well for continued growth and success in the market.

Rigel Pharmaceuticals reports robust Q2 sales and strategic growth focus

Rigel Pharmaceuticals showcased strong sales performance and product efficacy in Q2, positioning for future growth.
Challenges in managing expenses and strategic decision-making require careful navigation for sustained profitability.
Exploration of new opportunities and continued focus on innovation present avenues for revenue growth and market expansion.
Financial stability, ongoing development programs, and positive market feedback underpin Rigel's strategic direction and growth potential.

Rigel Pharmaceuticals excels in Q3 sales, eyes pipeline expansion

Rigel Pharmaceuticals demonstrated robust sales growth in Q3, managed expenses effectively, and aims for financial breakeven through operational efficiency. The company's strategic focus on pipeline expansion and partnerships positions it well for future growth and innovation.

Rigel Pharmaceuticals posts record sales, eyes growth with Gavreto acquisition

Rigel Pharmaceuticals reported strong financial performance with record sales and net income in Q4 2023.
The acquisition of Gavreto presents growth opportunities in the oncology market.
Challenges include transitioning Gavreto to commercial operations and competition in the targeted therapy space.

Rigel Pharmaceuticals reports strong Q1 performance and growth opportunities

Rigel Pharmaceuticals demonstrated strong performance in Q1 2024 with robust demand for key products and strategic acquisitions.
While facing challenges such as inventory management and financial breakeven, the company is well-positioned for growth.
Opportunities lie in continued sales growth, clinical advancements, and portfolio expansion through in-licensing deals.

Rigel Pharmaceuticals excels in Q2 with strong sales and pipeline progress

Rigel Pharmaceuticals delivered a robust performance in Q2 2024, driven by commercial success, pipeline advancements, and financial discipline. While facing challenges in clinical trial strategies and competitive landscape, the company is well-positioned to capitalize on growth opportunities through product expansions and strategic partnerships.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL ) Q1 2022 Earnings Conference Call May 3, 2022 4:30 PM ET Company Participants Dolly Vance - EVP, Corporate Affairs and General Counsel Raul Rodriguez - President and Chief Executive Officer Wolfgang Dummer - EVP and Chief Medical Officer Dave Santos - EVP and Chief Commercial Officer Dean Schorno - EVP and Chief Financial Officer Caroline Piatek - Associate Professor of Clinical Medicine Conference Call Participants Eun Yang - Jefferies Gary Nachman - BMO Capital Markets Kalpit Patel - B. Riley Securities Joseph Pantginis - H.C.

Rigel Pharmaceuticals, Inc.'s (RIGL) CEO Raul Rodriguez on Q1 2022 Results - Earnings Call Transcript

Rigel (RIGL) delivered earnings and revenue surprises of -33.33% and 9.50%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Rigel Pharmaceuticals (RIGL) Reports Q1 Loss, Misses Revenue Estimates

First quarter TAVALISSE® net product sales of $16.2 million and total revenues of $16.7 million T opline data from FORWARD study, a pivotal, Phase 3 clinical trial of fostamatinib in warm autoimmune hemolytic anemia (wAIHA), on track for mid-2022 Management to host a conference call and webcast today at 4:30 p.m. Eastern Time and will be joined by Key Opinion Leader and FORWARD trial investigator, Caroline Piatek, M.D.

Rigel Reports First Quarter 2022 Financial Results and Provides Business Update

– Key Opinion Leader and FORWARD trial investigator, Caroline Piatek, M.D., to join Rigel management to share experience and insight treating patients with wAIHA – SOUTH SAN FRANCISCO, Calif.

Rigel Announces Conference Call and Webcast to Report First Quarter 2022 Financial Results and Business Update

Creative Medical Technology Holdings

Eos Energy Enterprises

iBio

Here's what you need to know about trading penny stocks in April The post How to Trade Penny Stocks in April 2022 and 3 to Watch appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

How to Trade Penny Stocks in April 2022 and 3 to Watch

RIGL announced Q4'21 earnings in early March leading the stock to rally over 20%.

Rigel Pharmaceuticals: Why The Stock Is On A Run

SOUTH SAN FRANCISCO, Calif., March 8, 2022 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the publication of data in the American Journal of Hematology from the open label, multicenter, Phase 2 clinical study of fostamatinib in adults with warm antibody autoimmune hemolytic anemia (wAIHA) who had failed at least one prior treatment.

Rigel Announces Publication of Data from Phase 2 Clinical Study of Fostamatinib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia in the American Journal of Hematology

Rigel Pharmaceuticals, Inc. (RIGL) CEO Raul Rodriguez on Q4 2021 Results - Earnings Call Transcript

Rigel (RIGL) delivered earnings and revenue surprises of 0% and 3.71%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Rigel Pharmaceuticals (RIGL) Reports Q4 Loss, Misses Revenue Estimates

SOUTH SAN FRANCISCO, Calif., March 1, 2022 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the fourth quarter and full year ended December 31, 2021, including sales of TAVALISSE® (fostamatinib disodium hexahydrate) tablets for the treatment of adults with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.

Rigel Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif., Feb. 22, 2022 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its fourth quarter and year end 2021 financial results after market close on Tuesday, March 1, 2022.

Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Year End 2021 Financial Results and Business Update

RIGL's Tavalisse continues to undergo launch worldwide and royalties from ex-US partners may start to make a substantial contribution to RIGL's revenues in coming quarters. RIGL offers additional potential revenues from Tavalisse if the drug succeeds in a phase 3 study in warm autoimmune hemolytic anemia, due to report results in mid-2022.

Rigel PharmaceuticalsA Biopharma With A Free Shot On Goal In COVID-19, With A Pipeline As A Safety Net

SOUTH SAN FRANCISCO, Calif., Jan. 10, 2022 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, is scheduled to present a company overview at the 40th Annual J.P.

Rigel to Present at the J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Dec. 21, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced that its collaboration partner, Kissei Pharmaceutical Co., Ltd.

Fostamatinib Meets Primary Endpoint in Phase 3 Trial in Japan for Treatment of Chronic Immune Thrombocytopenia

SOUTH SAN FRANCISCO, Calif., Dec. 16, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has appointed Kamil Ali-Jackson to the company's Board of Directors.

Rigel Appoints Kamil Ali-Jackson to Board of Directors

COVID-19 variants continue to appear and vaccines are revealing their inability to prevent transmission. It is evident that COVID-19 is going to endure for the foreseeable future. It is obvious that there is going to be a growing need for additional therapeutics. Rigel's TAVALISSE has the prospects to be a vital contributor.

Rigel Pharmaceuticals: New Omicron Variant Keeps Tavalisse Treatment Prospects Alive

SOUTH SAN FRANCISCO, Calif., Nov. 15, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced plans to exit early-stage research and focus resources on its mid to late-stage development programs and its commercial efforts.

Rigel Sharpens Focus on Its Advanced Portfolio Opportunities

SOUTH SAN FRANCISCO, Calif., Nov. 9, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that Dean Schorno, the company's chief financial officer, will participate in the following virtual investor conferences in November: Jefferies Virtual London Healthcare Conference (November 18-19, 2021) Dean Schorno will present a company overview, which will be available for on-demand viewing starting on Thursday, November 18, at 8:00 a.m.

Rigel to Participate in Two Upcoming Investor Conferences

Rigel Pharmaceuticals, Inc. (RIGL) CEO Raul Rodriguez on Q3 2021 Results - Earnings Call Transcript

SOUTH SAN FRANCISCO, Calif., Nov. 2, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the third quarter ended September 30, 2021, including sales of TAVALISSE® (fostamatinib disodium hexahydrate) tablets for the treatment of adults with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.

Rigel Reports Third Quarter 2021 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif., Oct. 26, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its third quarter 2021 financial results after market close on Tuesday, November 2, 2021.

Rigel Announces Conference Call and Webcast to Report Third Quarter 2021 Financial Results and Business Update

As new variants continue to emerge, it is becoming more obvious that COVID-19 is not going away anytime soon. The world is going to need additional therapeutic options. The current lot of authorized or approved vaccines are somewhat effective against these new variants. Rigel's TAVALISSE is expected to help with the most severe symptoms regardless of the variant.

Rigel Pharma: Positive Data Supports Use Of Tavalisse In COVID-19 As Variants Subterfuge Vaccines

SOUTH SAN FRANCISCO, Calif., Sept. 2, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, and Dean Schorno, the company's chief financial officer, will participate in the following virtual investor conferences in September: Citi's 16th Annual Biopharma Conference (September 8-10, 2021) Raul Rodriguez will participate in a panel discussion entitled: "Sickle Cell, Beta-Thal, ITP & PKD - Measuring Industry Progress in Benign Hematology" on Friday, September 10 th at 12:30 p.m.

Rigel to Participate in Three Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Sept. 1, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced the publication of results from a Phase 2 clinical trial evaluating the safety of fostamatinib for the treatment of hospitalized patients with COVID-19, in Clinical Infectious Diseases , an official publication of the Infectious Disease Society of America.

News for Rigel Pharmaceuticals Stock (RIGL)